News | October 03, 2023
Briefs: Aurobindo Pharma and Balaxi Pharmaceuticals
Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company
Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company
Strides Pharma Science Limited to acquire 100% in Strides Pharma Services Pvt Ltd.
Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon
Aurobindo Pharma has reported total income of Rs. 6966.85 crores during the period ended June 30, 2023
The inspection closed with zero observations and a classification of No Action Indicated
Aurobindo will respond to the US FDA within the stipulated timelines
This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
The order marks a significant milestone for MMP Industries that will contribute to the company's revenue in the coming financial year
Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers
Subscribe To Our Newsletter & Stay Updated
